PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company today announced it will present results of recent clinical studies from its cardiovascular product portfolio at the 2015 European Society of Cardiology (ESC) Congress in London, August 29 to September 2.
The presentations at ESC 2015 will include a poster presentation of the Phase 1 results for ALN-PCSsc, a subcutaneously administered investigational RNAi therapeutic targeting PCSK9 being developed for the treatment of hypercholesterolemia. Alnylam Pharmaceuticals conducted this trial under a collaboration agreement with The Medicines Company and will present the results on Sunday, August 30 at 8:30 am British Standard Time (BST) (3:30 am Eastern Daylight Time (EDT)).
Help employers find you! Check out all the jobs and post your resume.
